Two different pharmacological approaches, not necessarily mutually exclusive, could be followed to address and inhibit MC activity in pathophysiological situations like liver fibrosis: i) MC stabilizers, such as disodium cromoglycate (cromolyn sodium), Tranilast, ketotifen, or many others (Figure 4); and/or ii) inhibitors of MC-selective enzymes (e.g., tryptase and chymase), and antagonists for receptors of typical MC mediators, such as histamine (receptors). Here, CMA1 is linked to Hepatic fibrosis.